Kwangdong Phar (009290) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Kwangdong Phar (009290) has a cash flow conversion efficiency ratio of 0.021x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩15.16 Billion ≈ $10.28 Million USD) by net assets (₩711.80 Billion ≈ $482.37 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how leveraged is Kwangdong Phar's balance sheet to measure how much of total assets are equity-financed.
Kwangdong Phar - Cash Flow Conversion Efficiency Trend (2011–2025)
This chart illustrates how Kwangdong Phar's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check earnings quality score of Kwangdong Phar to evaluate the quality of earnings relative to operating cash generation.
Kwangdong Phar Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Kwangdong Phar ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Exsitec Holding AB
ST:EXS
|
0.040x |
|
Putnam Master Intermediate Income Trust
NYSE:PIM
|
0.019x |
|
BBMG Corporation
F:9BM
|
0.032x |
|
Lollands Bank
CO:LOLB
|
-0.003x |
|
Home Center Holdings Co.Ltd
KQ:060560
|
0.000x |
|
Arbor Technology
TWO:3594
|
0.022x |
|
Takkt AG
XETRA:TTK
|
-0.017x |
|
Insight Molecular Diagnostics Inc.
NASDAQ:IMDX
|
0.715x |
Annual Cash Flow Conversion Efficiency for Kwangdong Phar (2011–2025)
The table below shows the annual cash flow conversion efficiency of Kwangdong Phar from 2011 to 2025. For the full company profile with market capitalisation and key ratios, see Kwangdong Phar market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | ₩711.80 Billion ≈ $482.37 Million |
₩82.34 Billion ≈ $55.80 Million |
0.116x | +688.50% |
| 2024-12-31 | ₩618.27 Billion ≈ $418.99 Million |
₩-12.15 Billion ≈ $-8.24 Million |
-0.020x | +1.46% |
| 2023-12-31 | ₩588.05 Billion ≈ $398.51 Million |
₩-11.73 Billion ≈ $-7.95 Million |
-0.020x | -117.37% |
| 2022-12-31 | ₩547.05 Billion ≈ $370.73 Million |
₩62.82 Billion ≈ $42.57 Million |
0.115x | +10.21% |
| 2021-12-31 | ₩527.24 Billion ≈ $357.31 Million |
₩54.94 Billion ≈ $37.23 Million |
0.104x | +129.22% |
| 2020-12-31 | ₩502.18 Billion ≈ $340.32 Million |
₩22.83 Billion ≈ $15.47 Million |
0.045x | -30.54% |
| 2019-12-31 | ₩447.46 Billion ≈ $303.24 Million |
₩29.29 Billion ≈ $19.85 Million |
0.065x | -46.89% |
| 2018-12-31 | ₩430.84 Billion ≈ $291.97 Million |
₩53.10 Billion ≈ $35.98 Million |
0.123x | +118.65% |
| 2017-12-31 | ₩416.30 Billion ≈ $282.12 Million |
₩23.46 Billion ≈ $15.90 Million |
0.056x | -21.78% |
| 2016-12-31 | ₩399.68 Billion ≈ $270.86 Million |
₩28.80 Billion ≈ $19.52 Million |
0.072x | -33.84% |
| 2015-12-31 | ₩377.73 Billion ≈ $255.98 Million |
₩41.14 Billion ≈ $27.88 Million |
0.109x | +4.55% |
| 2014-12-31 | ₩314.40 Billion ≈ $213.06 Million |
₩32.75 Billion ≈ $22.19 Million |
0.104x | -11.92% |
| 2013-12-31 | ₩290.82 Billion ≈ $197.09 Million |
₩34.39 Billion ≈ $23.31 Million |
0.118x | +33.16% |
| 2012-12-31 | ₩267.27 Billion ≈ $181.13 Million |
₩23.74 Billion ≈ $16.09 Million |
0.089x | -19.93% |
| 2011-12-31 | ₩249.52 Billion ≈ $169.09 Million |
₩27.68 Billion ≈ $18.76 Million |
0.111x | -- |
About Kwangdong Phar
Kwang Dong Pharmaceutical Co., Ltd. operates as a human healthcare provider in South Korea. It develops and sells OTC drugs in the areas of ophthalmic, mineral preparations, nutritious tonics, antipyretic, analgesic, anti inflammatory agents, circulating system, and vitamins; and ETC drugs in the areas of anti-malignant-tumor agent, obesity drug, appetite suppressant, antipyretic, analgesic, anti… Read more